Sublingual Immunotherapy

Sublingual Immunotherapy - Tongue's Immune Tune-up

• Mechanism: Allergen under tongue → oral dendritic cells → T-regulatory (Treg) cell induction → immune tolerance. Shifts Th2 to Th1 response.
• Indications: Allergic rhinitis/conjunctivitis (House Dust Mite, pollens), mild controlled asthma.
• Administration: Daily self-administration (tablets/drops). Held sublingually for 1-2 min before swallowing.
• Duration: Typically 3-5 years for sustained effect.
• Safety:
  • Common: Local oropharyngeal itching, swelling (usually transient).
  • Rare: Systemic reactions (anaphylaxis very rare, less than SCIT).
• Advantages: Home-based, ↑convenience, generally ↑safety profile vs. SCIT.
• Contraindications: Severe uncontrolled asthma, active eosinophilic esophagitis (EoE).

  ⭐ SLIT primarily induces allergen-specific IgG4 & IgA, and promotes T-regulatory (Treg) cell development, leading to immune tolerance.

Sublingual Immunotherapy - Drop Candidate Check

• Eligibility Criteria:
  • Age: >5 years (product-dependent).
  • IgE-mediated: Allergic rhinitis/conjunctivitis, mild/moderate controlled asthma.
  • Sensitization: Positive SPT/sIgE to specific allergen.
• Key Contraindications (CI):
  • Absolute:
    • Severe/uncontrolled asthma (FEV1 <70%).
    • Active autoimmune disease.
    • Beta-blocker therapy.
    • Eosinophilic Esophagitis (EoE).
  • Relative:
    • Poor adherence.
    • Significant oral lesions/inflammation.
    • Pregnancy (initiation CI; continuation case-by-case).
• First Dose Administration:
  • First dose in clinic.
  • 30-min observation post-dose.
  • Monitor local/systemic reactions (e.g., oral pruritus).

⭐ First dose of SLIT must be given under medical supervision with a 30-minute observation period to monitor for adverse reactions.

Sublingual Immunotherapy - Dose, Drops, Drama

• Mechanism: Targets mucosal dendritic cells → Treg induction, ↓Th2 response, ↑IgG4.
• Allergens: Common: House Dust Mite (HDM), grass/tree/ragweed pollens.
• Indications: Allergic rhinitis ± conjunctivitis, mild-moderate controlled allergic asthma.
• Contraindications: Severe/uncontrolled asthma (FEV1 < 70% predicted), concurrent beta-blocker use, active eosinophilic esophagitis (EoE), pregnancy (for initiation).
• Administration (Drops/Tablets):
  • Held under tongue for 1-2 minutes, then swallowed.
  • Daily dosing.
  • Typical duration: 3-5 years for sustained effect.
• Adverse Effects (Drama):
  • Local (common): Oral pruritus, throat irritation, GI upset. Usually mild, transient.
  • Systemic (rare): Urticaria, angioedema; anaphylaxis very rare.
  • First dose often administered under medical supervision.

⭐ SLIT offers a significantly better safety profile compared to SCIT (Subcutaneous Immunotherapy), with a much lower risk of systemic anaphylactic reactions, making it suitable for home administration after the first dose for many patients.

Sublingual Immunotherapy - Allergy Rivals Rumble

• Mechanism: Sublingual allergen delivery → oral Langerhans & dendritic cells → Treg induction → immune tolerance. 📌 SLIT: Safe, Lingual, In-home Treatment.
• Indications:
  • Allergic rhinitis/conjunctivitis (specific pollens like grass/ragweed, HDM).
  • Mild, controlled allergic asthma.
• Advantages (vs. SCIT):
  • ↑ Safety profile (significantly ↓ anaphylaxis vs SCIT).
  • Home administration.
  • Non-invasive (oral).
• Disadvantages:
  • Local AEs: oral/pharyngeal itching, swelling, GI upset (usually mild, transient).
  • Daily dosing.
• Duration: 3-5 years for sustained effect.
• Contraindications: Key CIs: Severe uncontrolled asthma, active autoimmune disease, prior EoE with SLIT.

⭐ First dose of SLIT (tablets for grass, ragweed, HDM) typically administered under medical supervision to manage potential initial reactions.

High‑Yield Points - ⚡ Biggest Takeaways

• SLIT offers a safer profile than SCIT, with a significantly lower anaphylaxis risk.
• Effective for allergic rhinitis and asthma, particularly with mono-sensitization to aeroallergens like HDM or pollens.
• First dose may be medically supervised; subsequent doses are typically self-administered daily at home.
• Most common adverse effects are local oropharyngeal symptoms (itching, mild swelling); severe systemic reactions are rare.
• Induces allergen-specific tolerance via T-regulatory cells (Tregs) and IgG4 blocking antibodies.